Raman Microspectroscopic Evidence for the Metabolism of a Tyrosine Kinase Inhibitor, Neratinib, in Cancer Cells

Karim Aljakouch, Tatjana Lechtonen, Hesham K. Yosef, Mohamad K. Hammoud, Wissam Alsaidi, Carsten Kötting, Carolin Mügge, Robert Kourist, Samir F. El-Mashtoly, Klaus Gerwert

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Tyrosine kinase receptors are one of the main targets in cancer therapy. They play an essential role in the modulation of growth factor signaling and thereby inducing cell proliferation and growth. Tyrosine kinase inhibitors such as neratinib bind to EGFR and HER2 receptors and exhibit antitumor activity. However, little is known about their detailed cellular uptake and metabolism. Here, we report for the first time the intracellular spatial distribution and metabolism of neratinib in different cancer cells using label-free Raman imaging. Two new neratinib metabolites were detected and fluorescence imaging of the same cells indicate that neratinib accumulates in lysosomes. The results also suggest that both EGFR and HER2 follow the classical endosome lysosomal pathway for degradation. A combination of Raman microscopy, DFT calculations, and LC-MS was used to identify the chemical structure of neratinib metabolites. These results show the potential of Raman microscopy to study drug pharmacokinetics.

Original languageEnglish
Pages (from-to)7250-7254
Number of pages5
JournalAngewandte Chemie / International Edition
Volume57
Issue number24
DOIs
Publication statusPublished - 11 Jun 2018

Fingerprint

Metabolites
Metabolism
Protein-Tyrosine Kinases
Microscopic examination
Cells
Imaging techniques
Pharmacokinetics
Cell proliferation
Cell growth
Discrete Fourier transforms
Spatial distribution
Labels
Fluorescence
Modulation
Degradation
Receptor Protein-Tyrosine Kinases
Intercellular Signaling Peptides and Proteins
N-(4-(3-chloro-4-(2-pyridinylmethoxy)anilino)-3-cyano-7-ethoxy-6-quinolyl)-4-(dimethylamino)-2-butenamide
Pharmaceutical Preparations

Keywords

  • cancer
  • label-free imaging
  • metabolism
  • Raman spectroscopy
  • tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Catalysis
  • Chemistry(all)

Cite this

Aljakouch, K., Lechtonen, T., Yosef, H. K., Hammoud, M. K., Alsaidi, W., Kötting, C., ... Gerwert, K. (2018). Raman Microspectroscopic Evidence for the Metabolism of a Tyrosine Kinase Inhibitor, Neratinib, in Cancer Cells. Angewandte Chemie / International Edition , 57(24), 7250-7254. https://doi.org/10.1002/anie.201803394

Raman Microspectroscopic Evidence for the Metabolism of a Tyrosine Kinase Inhibitor, Neratinib, in Cancer Cells. / Aljakouch, Karim; Lechtonen, Tatjana; Yosef, Hesham K.; Hammoud, Mohamad K.; Alsaidi, Wissam; Kötting, Carsten; Mügge, Carolin; Kourist, Robert; El-Mashtoly, Samir F.; Gerwert, Klaus.

In: Angewandte Chemie / International Edition , Vol. 57, No. 24, 11.06.2018, p. 7250-7254.

Research output: Contribution to journalArticleResearchpeer-review

Aljakouch, K, Lechtonen, T, Yosef, HK, Hammoud, MK, Alsaidi, W, Kötting, C, Mügge, C, Kourist, R, El-Mashtoly, SF & Gerwert, K 2018, 'Raman Microspectroscopic Evidence for the Metabolism of a Tyrosine Kinase Inhibitor, Neratinib, in Cancer Cells' Angewandte Chemie / International Edition , vol. 57, no. 24, pp. 7250-7254. https://doi.org/10.1002/anie.201803394
Aljakouch, Karim ; Lechtonen, Tatjana ; Yosef, Hesham K. ; Hammoud, Mohamad K. ; Alsaidi, Wissam ; Kötting, Carsten ; Mügge, Carolin ; Kourist, Robert ; El-Mashtoly, Samir F. ; Gerwert, Klaus. / Raman Microspectroscopic Evidence for the Metabolism of a Tyrosine Kinase Inhibitor, Neratinib, in Cancer Cells. In: Angewandte Chemie / International Edition . 2018 ; Vol. 57, No. 24. pp. 7250-7254.
@article{9717c350d92b435f9f68e323ea894afd,
title = "Raman Microspectroscopic Evidence for the Metabolism of a Tyrosine Kinase Inhibitor, Neratinib, in Cancer Cells",
abstract = "Tyrosine kinase receptors are one of the main targets in cancer therapy. They play an essential role in the modulation of growth factor signaling and thereby inducing cell proliferation and growth. Tyrosine kinase inhibitors such as neratinib bind to EGFR and HER2 receptors and exhibit antitumor activity. However, little is known about their detailed cellular uptake and metabolism. Here, we report for the first time the intracellular spatial distribution and metabolism of neratinib in different cancer cells using label-free Raman imaging. Two new neratinib metabolites were detected and fluorescence imaging of the same cells indicate that neratinib accumulates in lysosomes. The results also suggest that both EGFR and HER2 follow the classical endosome lysosomal pathway for degradation. A combination of Raman microscopy, DFT calculations, and LC-MS was used to identify the chemical structure of neratinib metabolites. These results show the potential of Raman microscopy to study drug pharmacokinetics.",
keywords = "cancer, label-free imaging, metabolism, Raman spectroscopy, tyrosine kinase inhibitors",
author = "Karim Aljakouch and Tatjana Lechtonen and Yosef, {Hesham K.} and Hammoud, {Mohamad K.} and Wissam Alsaidi and Carsten K{\"o}tting and Carolin M{\"u}gge and Robert Kourist and El-Mashtoly, {Samir F.} and Klaus Gerwert",
year = "2018",
month = "6",
day = "11",
doi = "10.1002/anie.201803394",
language = "English",
volume = "57",
pages = "7250--7254",
journal = "Angewandte Chemie / International Edition",
issn = "1433-7851",
publisher = "Wiley-VCH",
number = "24",

}

TY - JOUR

T1 - Raman Microspectroscopic Evidence for the Metabolism of a Tyrosine Kinase Inhibitor, Neratinib, in Cancer Cells

AU - Aljakouch, Karim

AU - Lechtonen, Tatjana

AU - Yosef, Hesham K.

AU - Hammoud, Mohamad K.

AU - Alsaidi, Wissam

AU - Kötting, Carsten

AU - Mügge, Carolin

AU - Kourist, Robert

AU - El-Mashtoly, Samir F.

AU - Gerwert, Klaus

PY - 2018/6/11

Y1 - 2018/6/11

N2 - Tyrosine kinase receptors are one of the main targets in cancer therapy. They play an essential role in the modulation of growth factor signaling and thereby inducing cell proliferation and growth. Tyrosine kinase inhibitors such as neratinib bind to EGFR and HER2 receptors and exhibit antitumor activity. However, little is known about their detailed cellular uptake and metabolism. Here, we report for the first time the intracellular spatial distribution and metabolism of neratinib in different cancer cells using label-free Raman imaging. Two new neratinib metabolites were detected and fluorescence imaging of the same cells indicate that neratinib accumulates in lysosomes. The results also suggest that both EGFR and HER2 follow the classical endosome lysosomal pathway for degradation. A combination of Raman microscopy, DFT calculations, and LC-MS was used to identify the chemical structure of neratinib metabolites. These results show the potential of Raman microscopy to study drug pharmacokinetics.

AB - Tyrosine kinase receptors are one of the main targets in cancer therapy. They play an essential role in the modulation of growth factor signaling and thereby inducing cell proliferation and growth. Tyrosine kinase inhibitors such as neratinib bind to EGFR and HER2 receptors and exhibit antitumor activity. However, little is known about their detailed cellular uptake and metabolism. Here, we report for the first time the intracellular spatial distribution and metabolism of neratinib in different cancer cells using label-free Raman imaging. Two new neratinib metabolites were detected and fluorescence imaging of the same cells indicate that neratinib accumulates in lysosomes. The results also suggest that both EGFR and HER2 follow the classical endosome lysosomal pathway for degradation. A combination of Raman microscopy, DFT calculations, and LC-MS was used to identify the chemical structure of neratinib metabolites. These results show the potential of Raman microscopy to study drug pharmacokinetics.

KW - cancer

KW - label-free imaging

KW - metabolism

KW - Raman spectroscopy

KW - tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85047500340&partnerID=8YFLogxK

U2 - 10.1002/anie.201803394

DO - 10.1002/anie.201803394

M3 - Article

VL - 57

SP - 7250

EP - 7254

JO - Angewandte Chemie / International Edition

JF - Angewandte Chemie / International Edition

SN - 1433-7851

IS - 24

ER -